ORIGINAL ARTICLE

Mutation of *DNAJC19*, a human homologue of yeast inner mitochondrial membrane co-chaperones, causes DCMA syndrome, a novel autosomal recessive Barth syndrome-like condition

K M Davey, J S Parboosingh, D R McLeod, A Chan, R Casey, P Ferreira, F F Snyder, P J Bridge*, F P Bernier*

J Med Genet 2006;43:385–393. doi: 10.1136/jmg.2005.036657

See end of article for authors' affiliations

Correspondence to:
Dr Peter J Bridge,
Molecular Diagnostic
Laboratory, Alberta
Children's Hospital, 1820
Richmond Road SW,
Calgary, Alberta T2T 5C7,
Canada; peter.bridge@
calgaryhealthregion.ca

Received 5 July 2005
Revised version received
5 July 2005
Accepted for publication
26 July 2005
Published Online First
3 August 2005

Background: A novel autosomal recessive condition, dilated cardiomyopathy with ataxia (DCMA) syndrome, has been identified in the Canadian Dariusleut Hutterite population, characterised by early onset dilated cardiomyopathy with conduction defects, non-progressive cerebellar ataxia, testicular dysgenesis, growth failure, and 3-methylglutaconic aciduria.

Objective: To map DCMA syndrome and identify the mutation underlying this condition.

Methods: A genome wide scan was undertaken on consanguineous Hutterite families using a homozygosity mapping approach in order to identify the DCMA associated chromosomal region. Mutation analysis was carried out on positional candidate genes in this region by sequencing. Reverse transcriptase polymerase chain reaction and bioinformatics analyses were then used to characterise the mutation and determine its effect on the protein product.

Results: The association of DCMA syndrome with a 2.2 Mb region of chromosome 3q26.33 was found. A disease associated mutation was identified: IVS3-1 G→C in the *DNAJC19* gene, encoding a DNAJ domain containing protein of previously unknown function (Entrez Gene ID 131118).

Conclusions: The *DNAJC19* protein was previously localised to the mitochondria in cardiac myocytes, and shares sequence and organisational similarity with proteins from several species including two yeast mitochondrial inner membrane proteins, Mdj2p and Tim14. Tim14 is a component of the yeast inner mitochondrial membrane presequence translocase, suggesting that the unique phenotype of DCMA may be the result of defective mitochondrial protein import. It is only the second human disorder caused by defects in this pathway that has been identified.

Dilated cardiomyopathy with ataxia (DCMA) syndrome is a novel autosomal recessive disorder found in the Dariusleut Hutterite population, an endogamous population of the great plains region of Canada and the northern United States.¹ The major clinical features of DCMA include a severe, early onset dilated cardiomyopathy (DCM), sometimes accompanied by long QT syndrome (LQTS). Prenatal or postnatal growth failure is universally seen, as is a cerebellar syndrome with ataxia, causing significant motor delays. Male genital anomalies are also frequently seen, and range from isolated cryptorchidism to severe perineal hypospadias. In addition, many patients have significant increases in urine organic acids, particularly of 3-methylglutaconic acid (3-MGC) and 3-methylglutaric acid (3-MGA). Additional features include optic atrophy, a mild increase in hepatic enzymes with microvesicular hepatic steatosis, a normochromic microcytic anaemia, and mild to borderline non-progressive mental retardation. The combination of clinical features varies among patients; however, cardiac involvement including DCM and LQTS, cerebellar ataxia, and raised levels of 3-MGC and 3-MGA are the hallmarks of DCMA syndrome.

Initially, DCMA syndrome presents in a very similar manner to Barth syndrome (type II 3-methylglutaconic aciduria), which is an X linked disorder caused by mutations in the *TAZ* gene and consists of DCM, raised 3-MGC and 3-MGA levels, skeletal myopathy, neutropenia, and growth failure.² The lack of skeletal myopathy and immunological features, however, as well as the cerebellar features and the

autosomal recessive inheritance, clearly distinguishes DCMA from Barth syndrome. DCMA syndrome also shares some resemblance to the other two defined classes of 3-methylglutaconic acidurias; however, the levels of 3-MGC and 3-MGA are too low in DCMA to suggest a primary block in the 3-methylglutaconyl-CoA hydratase enzyme as in type I 3-methylglutaconic aciduria, which is the result of mutations in the *AUH* gene.³ Cerebellar ataxia is a prominent feature in Costeff optic atrophy syndrome (type III 3-methylglutaconic aciduria), a disorder of the Iraqi Jewish population resulting from mutations in the *OPA3* gene. As the name suggests, early onset bilateral optic atrophy is the most prominent feature of this disorder and none of the cardiac features of DCMA syndrome has been noted in this disorder.⁴ Optic atrophy has been seen in a few patients with DCMA syndrome; however, it is not considered to be one of the major features of DCMA. Type IV 3-methylglutaconic aciduria includes all other cases of 3-methylglutaconic aciduria that cannot be included in types I, II, or III. Neurological, motor, and sensory defects are common within this category, as well as cases of DCM and liver dysfunction. Cases included within the category probably result from various different causes and defects, as increases in both 3-MGC and 3-MGA have been reported in several inborn errors

Abbreviations: DCM, dilated cardiomyopathy; DCMA, dilated cardiomyopathy with ataxia; LQTS, long QT syndrome; 3-MGA, 3-methylglutaric acid; 3-MGC, 3-methylglutaconic acid

of metabolism and also during pregnancy.⁵ All cases of DCMA that have been identified thus far are from the Dariusleut Hutterite population; however, it is possible that other cases have been included within this category for lack of a better classification, and thus DCMA syndrome represents an additional category of the 3-methylglutaconic acidurias.

The characteristics of endogamous populations make it possible to map genetic conditions using a homozygosity mapping approach.⁶ By this approach, we aimed to map DCMA syndrome by identifying regions of the genome that are identical by descent between affected patients from different consanguineous families. Here we report the association of DCMA syndrome with a 2.2 Mb segment of 3q26.33 and the identification of a splice mutation in a novel gene *DNAJC19* in DCMA patients. The *DNAJC19* protein shares similarity with the yeast TIM14 protein, a component of the mitochondrial protein import system, and DCMA syndrome may represent only the second human disorder associated with defects in mitochondrial protein import.

METHODS

Patients and controls

This study was approved by the conjoint health research ethics board at the University of Calgary. Informed consent was obtained from patients and family members, and genomic DNA was extracted from either cultured fibroblasts or peripheral blood leucocytes by standard phenol chloroform extraction. Fibroblast cells were cultured in MEM medium (Gibco, Gaithersburg, Maryland, USA), with 10–12% fetal bovine serum at 37°C and 5% CO₂. A set of 250 genomic DNA samples of various ethnicities was used to check whether the *DNAJC19* IVS3-1 G→C mutation exists as a polymorphism in the general population. Genomic DNA from these controls was extracted from peripheral blood lymphocytes by a standard phenol chloroform procedure.

Genome scan

Using a homozygosity mapping approach,⁶ a complete genome scan was undertaken by genotyping 400 microsatellite markers covering the entire genome to an average density of 10 cM using the ABI PRISM MD-10 linkage mapping set, version 2 (Applied Biosystems, Foster City, California, USA). The genome scan was carried out on five severely affected Hutterite patients meeting inclusion criteria defined by at least two of the following features: dilated cardiomyopathy, 3-methylglutaconic aciduria, and genital anomalies. Fine mapping around potential candidate regions was done by selecting additional microsatellite markers from the ABI PRISM HD-5 Linkage Mapping Set (Applied Biosystems), and NCBI STS map, and by genotyping additional patients and unaffected family members. UniSTS accession numbers for these markers are provided in the electronic database information section below.

Mutation screen

Mutation analysis of candidate genes was undertaken by bidirectional sequencing of predicted exons and splice junctions from genomic DNA from an affected patient, an obligate carrier, and a non-carrier, as determined by the pattern of inheritance of the disease associated haplotype. Sequence data were analysed by subtraction analysis using the Staden package. Entrez Gene entries for positional candidate genes are provided in the electronic database information section.

The *DNAJC19* gene was polymerase chain reaction (PCR) amplified in three segments using the following primers (letters in brackets indicate primer positions shown in fig 1B): *segment 1*, corresponding to exon 6 (1263 base pairs (bp)), forward (P): 5'-GAAGTTTAGACGGTAGGTAGTATAA, reverse (I): 5'-GCTAAATCTCCCTCAGATAAG; *segment 2*, corresponding to exons 4 and 5 (1298 bp), forward (H): 5'-ATTATCCCA-TTAATAACTATTGGTC, reverse (E): 5'-CTAAATACCT-CGGAATTG; and *segment 3*, corresponding to exons 1, 2 and 3 (1955 bp), forward (D): 5'-CAGGAGAATGGGTCC-AAAGCAATCA, reverse (A): 5'-CCGCCACCCCTTCAACCAAC.

Figure 1 Map of the chromosome 3q DCMA candidate region. (A) Refined map interval spanning 23.9 cM from 3q26.2-q27.3 between markers D3S1282 and D3S1262. The markers in bold represent the core disease associated region of approximately 2.2 Mb (see electronic database information section for UniSTS accession numbers). (B) An expanded map of the genomic organisation of the *DNAJC19* gene. The six exons extend over 5.2 kb. The coding sequence is indicated in dark grey and the non-coding sequence is in light grey. The locations of primers used for mutation screening are indicated. Primers used for amplification of three genomic segments are indicated by capital letters. Additional primers used for sequencing are shown in lower case. Primers used for reverse transcriptase polymerase chain reaction analysis are also indicated.

Amplifications were carried out using the Platinum Taq buffer system (Invitrogen, San Diego, California, USA) with 2.5 mM magnesium chloride, and an annealing temperature of 60°C.

Sequencing reactions were carried out at 60°C using ABI BigDye version 3.1 (Applied Biosystems) and the following primers: *exon 1*, forward: primer A, sequence shown above; *exon 1*, reverse (b): 5'-AGCTGAGGTTGAGGCCTGGG; *exons 2 and 3*, forward (c): 5'-ATGGAAGAATGGGCAAAATG; *exons 2 and 3*, reverse: primer D, sequence shown above; *exon 4*, forward: primer E, sequence shown above; *exon 4*, reverse (f): 5'-AAGGAGAGAAGGTCTTTCTT; *exon 5*, forward (g): 5'-GTCTTTAATTGGCCTTATG; *exon 5*, reverse: primer H, sequence shown above; *exon 6*, forward-1: primer I, sequence shown above; *exon 6*, forward-2 (j): 5'-AAATGCCTCAGAGCTACAAT; *exon 6*, forward-3 (l): 5'-TCTTATTCGGTGGAAGGCT; *exon 6*, forward-4 (n): 5'-TGGGATTACAGGCATGAGTA; *exon 6*, reverse-1 (k): 5'-ATCCCCAAATTTAAACAAGA; *exon 6*, reverse-2 (m): 5'-TCCAAGTTGCCAGGCCAGTT; *exon 6*, reverse-3 (o): 5'-AGAAATAGCCAAGTGAAGGA; *exon 6*, reverse-4: primer P, sequence shown above.

The *DNAJC19* IVS3-1 G→C mutation abolishes a *StuI* cut site. Controls were tested for the presence of this mutation by PCR amplification of *DNAJC19* segment 2 (primers and conditions given above). PCR product (10 µl) was digested for two hours in 3 units of *StuI* enzyme (Roche) and run on 1.5% agarose. The normal G allele when cut gives 1160 bp and 138 bp bands. The mutant C allele remains uncut and is a 1298 bp band. The G/C heterozygote gives 1298 bp, 1160 bp, and 138 bp bands (data not shown).

Reverse transcriptase polymerase chain reaction and tissue expression

Reverse transcriptase polymerase chain reaction (RT-PCR) was carried out on total RNA isolated from fibroblasts using the Qiagen RNeasy midi kit (Qiagen Inc, Valencia, California, USA). *DNAJC19* specific primers were designed to amplify a 525 bp cDNA product corresponding to the full length coding sequence and the 5' and 3' UTR boundaries: RT forward primer (RTF), 5'-GGTAAAGCGTGCGAGGT; RT reverse primer (RTR), 5'-AAAATTGTAGCTCTGAGGCATT. RT-PCR was done using the Superscript One-Step RT-PCR kit (Gibco) with an initial incubation at 46°C for 20 minutes followed by 38 cycles at an annealing temperature of 55°C. cDNA RT-PCR products were sequenced using the RTF and RTR primers. Gene expression studies used cDNA panels containing a number of fetal and adult tissue types (BD Clontech multiple tissue cDNA panels I and II, and fetal multiple tissue cDNA panel (Clontech Laboratories, Palo Alto, California, USA). The cDNA panels were amplified using Platinum Taq buffer (Invitrogen) and the above RTF and RTR primers with an annealing temperature of 60°C, and run on 1.5% agarose.

Informatics

Map positions of markers and positional candidate gene models were identified using the National Center for Biotechnology Information (NCBI) map viewer. All primers were designed using Oligo 6. Protein domain predictions were made using the conserved domain architecture retrieval tool (CDART), and similarity searches based on this domain architecture were carried out using the reverse position specific BLAST algorithm. Other predictions were made using proteomics tools available from the expert protein analysis system (ExPASy). Multiple alignments were constructed using ClustalW, and alignments were visualised using Genedoc. Uniform resource locators for these tools and GenBank identification numbers for aligned sequences are provided in the electronic database information section below.

Table 1 Summary of the clinical features of dilated cardiomyopathy with ataxia syndrome

Patient No	Sex	Alive at/diagnose at	DCM	Long QT	IUGR	FTT/growth failure	Cerebellar signs/ataxia	Microcytic anaemia	RaisedAST/ALT	Hepatic steatosis	Male genitalia	Mild/borderline MR	Optic atrophy	Malformations	Other
6	M	(8 m)			+	+	+	+	+		C	+		D	Mullerian remnants
1	M	13 y			+	+		+	+		C,H			D, A	
5	M	(4 m)			+	+		+	+		C,H				
22	F	(23 m)	+		+	+		+	+	+	C,H	+			
21	F	(13 m)	+	+	+	+		+	+	+	C,H	+			
7	M	(4 y)	+		+	+	+	+	+		C	+			
8	M	(16 m)	+		+	+	+	+	+	+	C	+			
19	M	(18 m)	+		+	+	+	+	+	+	C	+			
16	M	11 y	+	+		+	+	+	+		C,H	+		+	
20	F	(3 y)	+		+	+	+	+	+		C,H	+			Arachnoid cyst Hypothyroidism
10	M	21 y	+			+	+	+	+		C,H	+			
23	F	(4 y)	+		+	+	+	+	+		C,H	+			
11	M	13 y	+			+	+	+	+						
9	F	(9 m)				+	+	+	+	+					Seizures
24	F	10 y	+			+	+	+	+						
12	M	22 y		+		+	+	+	+						
13	F	19 y				+	+	+	+						Seizures
25	M	(8 y)	+		+	+	+	+	+	+	C	+			

A, atrial septal defect; ALT, alanine transaminase; AST, aspartate transaminase; DCM, dilated cardiomyopathy; F, female; FTT, failure to thrive; H, hypospadias; IUGR, intrauterine growth retardation; M, male; m, months; MR, mitral regurgitation; y, years.

RESULTS

Clinical histories

Clinical features of our 18 study patients are summarised in table 1.

Eleven of these patients had either echocardiographic or pathological features at necropsy consistent with a diagnosis of DCM. The onset of the DCM was always before the age of three years, and over 70% of affected patients died from either progressive cardiac failure or sudden cardiac death. Some patients improved with standard medical treatment, and complete resolution of the DCM was seen in two patients, with normalisation of the echocardiogram, even following withdrawal of cardiac drug treatment. Long QT syndrome was often seen in the patients with DCM; however, it was also seen in those without clinical or echocardiographic evidence of DCM. Prenatal or postnatal growth failure, or both, was universally seen. All patients over the age of two years had a cerebellar syndrome with ataxia resulting in significant motor delays, although most patients ambulate independently. Male genital anomalies ranging from isolated cryptorchidism to severe perineal hypospadias were common and were secondary to testicular dysgenesis, based on the frequent findings of small atrophic testes and incomplete testosterone rise after human chorionic gonadotrophin stimulation. A few male patients also had Mullerian remnants and therefore both androgen and anti-Mullerian hormone synthesis was impaired, consistent with testicular dysgenesis. Additional features included optic atrophy, mild increases in hepatic enzymes with microvesicular hepatic steatosis, a normochromic microcytic anaemia, and mild to borderline non-progressive mental retardation.

Many patients were found to have significant increases in urine organic acids, particularly of 3-methylglutaconic (3MGC) and 3-methylglutaric acid (3MGA). Quantitative measurement of the 3MGC and 3MGA⁷ was carried out in affected patients, controls, and unaffected relatives. Affected patients consistently showed five- to 10-fold increases in both plasma and urine 3MGC and 3MGA (data not shown).

Genome scan

To identify the chromosomal region associated with the DCMA syndrome, we undertook a genome scan using a homozygosity mapping approach in five severely affected patients⁶ (fig 2A, individuals 1, 7, 9, 10, and 11). Following the initial scan, none of the markers was homozygous in all five patients. Homozygosity was suggested, however, at nine loci with either four of five, or three of five, patients homozygous for the same allele, and the non-homozygotes sharing the same allele on one chromosome (*D2S2211*, *D2S325*, *D3S1565*, *D5S408*, *D12S1723*, *D12S310*, *D14S74*, *D22S420*, and *D22S315*). Fine mapping around these candidate regions ruled out evidence of an ancestral homozygous haplotype in all but the chromosome 3 locus (*D3S1565*). Additional saturating markers enabled the identification of an extended disease associated haplotype of 23.9 cM on chromosome 3q26.2–q27.3, between markers *D3S1282* and *D3S1262* (fig 1A). An additional 10 affected patients, as well as any available unaffected family members, were genotyped, reducing this to a core region of 2.2 megabases between markers *D3S3603* and *D3S2314* on 3q26.33 (figs 1A and 2A).

Mutation screening

To identify the DCMA syndrome mutation in our patients, all predicted exons and splice junctions were bidirectionally sequenced for all 12 positional candidate genes in the minimal region. We identified a G→C transversion in the conserved AG splice acceptor site of intron 3 of the *DNAJC19* gene (*IVS3-1G→C*) (fig 2B). *DNAJC19* was previously uncharacterised, and comprises six exons spanning 5.2 kb

of genomic sequence (fig 1B). All affected patients included in this study for whom DNA samples were available (*n* = 16) were homozygous for this mutation, while unaffected parents showed a pattern of inheritance of this mutation consistent with their carrier status of the affected haplotype (*n* = 8). No unaffected siblings were homozygous for this haplotype (*n* = 3) (fig 2A). The *IVS3-1 G→C* mutation eliminates a *StuI* restriction site. Mutation screening of 236 unaffected controls by *StuI* digest revealed only the normal G/G genotype (data not shown). No mutations were identified in any of the other 11 positional candidates in this region.

DNAJC19 gene expression

The *DNAJC19* *IVS3-1G→C* mutation was predicted to prevent splicing of the exon 4 coding sequence into the *DNAJC19* mRNA (Δ ex4). To confirm this effect, *DNAJC19* specific RT-PCR analysis was carried out on total fibroblast RNA from an affected patient and an unaffected control. A single 445 bp product was detected in the affected patient, while two products—a dominant 525 bp band and a minor 445 bp band—were detected in the control sample (fig 3A).

To examine expression of the *DNAJC19* gene in various tissue types, we PCR amplified the *DNAJC19* cDNA, using multiple tissue first strand cDNA panels. The *DNAJC19* transcript is ubiquitously expressed, as we detected a dominant 525 bp product corresponding to the full length *DNAJC19* cDNA as well as a minor product of 445 bp in all tissue types tested (fig 3B). To confirm the identity of these products, we gel purified and sequenced the 445 bp band from the patient RT-PCR sample, as well as both the 445 bp and 525 bp bands from the adult leucocyte sample from the cDNA panel. The 445 bp products from the affected patient and the wild type adult leucocyte sample are missing coding sequence corresponding to exon 4 (Δ ex4), while the predominant 525 bp product from the leucocyte sample corresponds to the predicted full length mRNA sequence for the *DNAJC19* gene (fig 3C).

Characterisation of *DNAJC19*

As *DNAJC19* is a previously uncharacterised gene, various informatics analyses were applied to examine the consequence of the *IVS3-1 G→C* mutation on the *DNAJC19* protein, and to identify any functional domains. The full length *DNAJC19* gene encodes a predicted 116 amino acid protein with a molecular mass of 12.5 kDa. Translation of the Δ ex4 transcript is predicted to produce a truncated protein of 47 amino acids with a theoretical molecular weight of approximately 5 kDa. The first 43 residues encoded by exons 1–3 would be preserved; however, skipping of exon 4 produces a reading frame shift in the exon 5 coding sequence resulting in a predicted aberrant four amino acid substitution (PYCQ) followed by a termination codon.

CDART analysis of the 116 amino acid *DNAJC19* protein indicates the presence of a conserved DNAJ domain from residues 66 to 116 at the C-terminus of the protein. A single transmembrane segment was identified using the TMpred program at the N-terminus of the protein from residues 4 to 23 (fig 4A). In addition, the region directly following the transmembrane domain is predicted to form an amphipathic α helical structure that is rich in positively charged residues, resembling a mitochondrial targeting sequence. If translated, the truncated protein encoded by the Δ ex4 transcript would contain only a transmembrane domain, and would completely lack the DNAJ domain.

Similarity searches were performed using rpsBLAST to identify proteins in other species that have similar domain architecture to *DNAJC19*. A number of similar proteins were identified that contained a highly conserved DNAJ domain at the C-terminus and a predicted transmembrane domain

Figure 2 The *DNAJC19* IVS3-1G→C mutation is associated with a dilated cardiomyopathy syndrome in consanguineous Hutterite families. (A) Patients and families included in this study show an extended common haplotype from *D3S1282* to *D3S1262*; alleles included in this haplotype are highlighted in grey with the core disease associated region highlighted in dark grey. The genotypes for the *DNAJC19* IVS3-1G→C mutation are also shown. Patient numbers correspond with numbers in table 1. DNA was unavailable for patients 6 and 22; however, these patients were included in the study cohort, based on their clinical phenotypes. DNA for patient 25 was unavailable for haplotyping, but the clinical diagnosis was confirmed by genotyping for the *DNAJC19* IVS3-1G→C mutation at a later date. (B) Electropherograms showing *DNAJC19* IVS3-1G→C genotypes from an affected patient (C/C), an obligate carrier (G/C), and a wild type individual (G/G). These bases are reversed on the reverse sequence, as indicated below the figure.

positioned towards the N-terminus, a selection of these are shown in figure 4B.

DISCUSSION

DCMA syndrome is a novel autosomal recessive disorder that shares some clinical similarity with the X linked Barth syndrome and the other 3-methylglutaconic acidurias. The three defined classes of 3-methylglutaconic aciduria—3-methylglutaconyl-CoA hydratase deficiency (type I), Barth syndrome (type II), and Costeff optic atrophy syndrome (type III)—are all caused by defects in known or predicted mitochondrial proteins.²⁻⁵ In addition, raised 3-methylglutaconic acid is a common finding in respiratory chain disorders. The major clinical and biochemical features of DCMA syndrome are consistent with a mitochondrial cytopathy; however, this degree of testicular dysgenesis has to our knowledge never been reported in a mitochondrial disorder. The autosomal recessive pattern of inheritance, and the unique combination of clinical features in DCMA syndrome, distinguishes it from the other 3-methylglutaconic acidurias and suggests that DCMA syndrome is a fifth type of 3-methylglutaconic aciduria.

To date, DCMA syndrome has only been seen in patients from the Dariusleut Hutterite population. It is possible that additional DCMA patients may exist outside this population,

potentially in European ancestral populations from which the Hutterites descended. If this is the case, these patients may have been misclassified within the type IV 3-methylglutaconic aciduria category for lack of a better diagnosis, as cases of dilated cardiomyopathy not attributed to Barth syndrome have been included in this category.

Using a homozygosity mapping approach,⁶ we identified an ancestral haplotype on chromosome 3q26.2–3q27.3 segregating with DCMA syndrome. Mutation analysis of positional candidate genes identified a splice site mutation in a previously uncharacterised gene, *DNAJC19*, which encodes a mitochondrial DNAJ domain-containing protein.⁸ This mutation was predicted to cause aberrant splicing and result in the loss of the full length *DNAJC19* transcript. RT-PCR analysis confirmed the splice defect (Δ ex4), and in affected patients homozygous for the IVS3-1G→C mutation splicing is completely abnormal and a full length *DNAJC19* transcript is not produced. The presence of the Δ ex4 transcript in wild type tissues in addition to the full length transcript may indicate that alternative splicing is common at this site.

Proteins containing the DNAJ domain are typically involved in molecular chaperone systems of the Hsp70/Hsp40 type. These chaperone systems aid in folding and assembly of newly synthesised proteins, as well as preventing abnormal folding and aggregation of proteins during stress

Figure 3 Expression analysis of *DNAJC19*. (A) Reverse transcriptase polymerase chain reaction (RT-PCR) analysis of *DNAJC19* using gene specific primers and RNA extracted from cultured fibroblasts from an affected patient and a non-Hutterite normal control. Two bands were amplified from the normal control, one of 525 base pairs (bp) corresponding to the full length cDNA, and a second less abundant band of 445 bp. In the affected patient, only the 445 bp band was detected. The predicted size of the product from a *DNAJC19* transcript missing the exon 4 coding sequence is 445 bp. (B) Expression analysis of *DNAJC19* was undertaken using gene specific primers and various normalised first strand cDNA preparations from fetal and adult tissues. Both cDNAs were found expressed in all tissues, with the full length cDNA more abundant in all tissues tested except for adult leucocytes. Tissue types tested: bn, adult brain; co, adult colon; fb, fetal brain; fh, fetal heart; fk, fetal kidney; fl, fetal lung; flv, fetal liver; fsk, fetal skeletal muscle; fsp, fetal spleen; ft, fetal thymus; h, adult heart; k, adult kidney; l, adult lung; lk, adult leucocytes; lv, adult liver; ov, adult ovary; p, adult prostate; pa, adult pancreas; pl, placenta; si, adult small intestine; sk, adult skeletal muscle; sp, adult spleen; ts, adult testis; ty, adult thymus. Each set was run with G3PDH, glyceraldehyde-3-phosphate dehydrogenase control; C, positive control; b, water blank. (C) To determine the identity of the cDNA products, the 445 bp cDNA from the affected patient, the 445 bp and 525 bp bands from adult leucocytes were sequenced. Both the cDNA from the affected individual, and the 445 bp band from leucocytes were found to have exons 3 and 5 spliced together and the absence of exon 4 coding sequence (Δ ex4). The 525 bp band corresponded to the full coding sequence of *DNAJC19*. The Δ ex4 cDNA detected in normal tissues and control are thought to be a normal splice variant.

conditions. The Hsp70 protein binds unfolded hydrophobic domains of the substrate protein, while the Hsp40 co-chaperone aids in loading the substrate protein onto Hsp70

and stimulates Hsp70 binding activity through the DNAJ domain.⁹ The domain architecture of the *DNAJC19* protein is unusual among members of the DNAJ protein family, in that

Figure 4 DNAJC19 has an unusual domain architecture with respect to other DNAJ proteins and similar proteins are found in various species. (A) Graphical representation of the domain structure of *H sapiens* DNAJC19 v the *E coli* DNAJ/HSP40 protein. The DNAJC19 protein contains only the DNAJ domain (pfam00226.11), which is located at the C-terminus following a predicted transmembrane domain. This is in contrast with the *E coli* DNAJ/HSP40 protein which is the classical example of a DNAJ protein. The DNAJ domain (pfam00226.11) is located at the N-terminus of the protein followed by a glycine/phenylalanine-rich linker domain, a cysteine-rich domain (pfam00684.11) containing four copies of a zinc-finger-like motif (CXXCXGXG), and a C-terminal domain (pfam01556.11) of unknown function. (B) ClustalW multiple sequence alignment of DNAJC19 homologues (see Electronic-Database Information section for GenBank identification numbers). The conserved helix structures of the DNAJ domain are underlined; the DNAJ domains of these proteins only contain three of the helices that make up the classical tetrahelical DNAJ domain. They all also contain the absolutely conserved HPD motif which is indicated by (***). Highlighted regions indicate conserved blocks of sequence. Residues highlighted in black indicate positions with highest degree of conservation and those highlighted in grey indicate less highly conserved positions. Gaps introduced to optimise the alignment are indicated by dashes (-). Alignment was adjusted in Genedoc based on previously published alignments.

the DNAJ domain is positioned at the C-terminus of the protein following a single transmembrane domain (fig 4A).¹⁰ This is in contrast with *E coli* DNAJ, the classical example of a DNAJ co-chaperone, where the DNAJ domain is located at the N-terminus, and is followed by other conserved domains involved in its other functions (fig 4A).^{9, 10} In addition, the classical DNAJ proteins are soluble, whereas the predicted transmembrane domain of DNAJC19 suggests that it may be membrane bound. Similarity searches based on this domain architecture indicate that proteins similar to DNAJC19 are present in various species having a highly conserved C-terminal DNAJ domain and an upstream transmembrane domain (fig 4B). Two of these—the yeast Tim14 and Mdj2p proteins—are components of the mitochondrial inner membrane.^{11–14}

The role of Tim14 has recently been elucidated in yeast, where it is a component of the TIM23 inner membrane translocase complex and is an essential protein required for cell viability.^{12–14} The TIM23 complex facilitates the import of mitochondrial presequence containing proteins through the inner membrane. Tim14 is an essential subunit of the TIM23 complex, functioning with mitochondrial Hsp70, and the Tim16^{15, 16} and Zim17^{17, 18} proteins as a component of the import motor subcomplex. This import motor is an adaptation of the Hsp70/Hsp40 chaperone system using a membrane bound DNAJ domain to stimulate binding of mitochondrial Hsp70 (mtHsp70) to the incoming peptide chain at its point of entry. This is thought to aid in import through the TIM23 translocase in two ways: first, ATP driven conformational changes in mtHsp70 upon substrate binding are thought to pull the incoming peptide into the matrix; and

second, binding of mtHsp70 to the unfolded chain prevents backsliding through the Tim23 import pore.¹⁹ This system couples the chaperone function of mtHsp70 with import, aiding in proper folding and assembly of newly imported matrix proteins.

The functions of the other DNAJC19-like proteins are as yet unknown, and it is unclear whether DNAJC19 is in fact the human orthologue of yeast Tim14. The yeast Mdj2p protein is a known component of the inner mitochondrial matrix; however, a defined function has yet to be identified for it. What is known is that Mdj2p is not an essential protein for viability, and it can partially compensate for the loss of Mdj1p, the major mitochondrial hsp40 homologue in yeast.¹¹ A second human protein, methylation controlled J protein (MCJ), is also included within this group.²⁰ A differential pattern of expression has been noted for MCJ in wild type cell lines dependent on the methylation status of a CpG island in the first intron of the MCJ gene.^{21, 22} Differences in expression of MCJ have been noted in ovarian cancers and may be associated with the cellular response to chemotherapeutic drugs.^{20, 22} A proteomic screen of the mitochondria of human cardiac myocytes identified DNAJC19 as a component of the mitochondrial proteome; however, MCJ was not identified in this screen.⁸ Like DNAJC19, MCJ shares sequence similarity with the yeast Tim14 and Mdj2p proteins. The differential pattern of expression of MCJ, however, argues against a housekeeping-type role as would be expected for a Tim14 orthologue. The identification of DNAJC19 in the mitochondrial proteome, along with its role in the DCMA syndrome phenotype, are congruent with the DNAJC19 protein being orthologous with the yeast Tim14 or Mdj2p proteins.

The similarity of DNAJC19 with the yeast Tim14 protein suggests that the phenotype of DCMA syndrome might result from the defective import and assembly of presequence containing mitochondrial proteins through the TIM23 translocase pathway. Defects in mitochondrial import have been reported previously to cause a progressive neurodegenerative condition, Mohr-Tranebjaerg syndrome, which includes sensorineural deafness, vision loss, mental retardation, and a movement disorder.²³ Mohr-Tranebjaerg syndrome is caused by mutations in *DDP1*,²⁴ the orthologue of yeast *Tim8*, which appears to be important in facilitating the transfer of Tim23, the core component of the TIM23 inner membrane translocase complex, from the translocase of the outer membrane (TOM) through the intermembrane space to the TIM22 translocase.^{19–25} The phenotype of Mohr-Tranebjaerg syndrome is therefore thought to result from abnormal assembly of the TIM23 transporter. Mohr-Tranebjaerg syndrome is the only known genetic disorder involving a defect in the mitochondrial protein import system.

Over 99% of mitochondrial proteins in humans are nuclear encoded.¹⁹ Thus the mechanisms for transfer and assembly of the cytoplasmically synthesised precursor proteins into or across both mitochondrial membranes are of critical importance. The potential association of DCMA syndrome with mitochondrial protein import defects suggests that this may be an important cause of mitochondrial cytopathies. Mechanisms for protein transport and assembly in the mitochondria continue to be elucidated, largely on the basis of work in the yeast *S cerevisiae*. The relevance of these studies to our understanding of the pathogenic mechanisms underlying human mitochondrial diseases, however, remains poorly understood and further development of this area will benefit not only from the identification of additional human diseases but also from the development of mammalian model systems based on the studies already completed in simple eukaryotes. The present discovery of the association of DCMA syndrome with a mutation in the *DNAJC19* gene will help to expand our insight into the role of mitochondrial import and trafficking in human cytopathies.

ELECTRONIC DATABASE INFORMATION

Entrez Genome Map Viewer, cytogenetic, physical and genetic maps of human chromosome 3 (<http://www.ncbi.nlm.nih.gov/mapview/maps.cgi?taxid=9606&chr=3>)

Oligo 6 primer design software (<http://www.oligo.net>)

Entrez UniSTS entries for markers making up ancestral DCMA syndrome haplotype (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unists>): *D3S1282* [68930], *D3S3523* [57600], *D3S3725* [73565], *D3S3520* [17983], *D3S1565* [63165], *D3S2425* [82628], *D3S2421* [13287], *D3S2427* [37149], *D3S3676* [30955], *D3S3715* [74051], *D3S1754* [9710], *D3S3699* [43474], *D3S3603* [30527], *D3S3662* [78965], *D3S2314* [15487], *D3S1618* [72781], *D3S1571* [8133], *D3S2399* [10726], *D3S1617* [39046], *D3S1262* [53008]).

Entrez gene entries for positional candidates in the region *D3S3603* to *D3S2314* (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene>): LOC131054 similar to RalA binding protein 1 (RalBP1) [131054], TTC14 tetratricopeptide repeat domain 14 [151613], hypothetical protein DKFp434A128 [339829], LOC389178 similar to RING finger protein 13 [389178], LOC402151 similar to β -actin [402151], FLYWCH-type zinc finger 1-like [391594], LOC391595 similar to 60S ribosomal protein L32 [391595], fragile X mental retardation, autosomal homologue 1 [8087], DNAJ (Hsp40) homologue, subfamily D, member 2 [131118], SOX2 overlapping transcript (non-coding RNA) [347689], SOX2 SRY(sex

determining region Y)-box 2 [6657], LOC401102 similar to zinc finger, CCHC domain containing 10 [401102].

ACKNOWLEDGEMENTS

We thank the Dariusleut Hutterite community, especially the individuals with this syndrome and their families, and the referring physicians for their participation and cooperation in this study. We also thank the staff of the Alberta Children's Hospital Molecular Diagnostic Laboratory for their technical expertise. Special thanks to Dr Kym Boycott and Jayda Miller for their contributions. We acknowledge support from the Alberta Children's Hospital Research Foundation, The Garrod Association and the Canadian Institutes of Health Research Training Program in Genetics, Child Health and Development.

Authors' affiliations

K M Davey, J S Parboosingh, D R McLeod, R Casey, F F Snyder, P J Bridge*, F P Bernier*, Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada
A Chan, Department of Medical Genetics, University of Alberta, Edmonton, Alberta
P Ferreira, Alberta Children's Hospital, Calgary, Alberta

*These two authors contributed equally to this work.

Conflicts of interest: none declared

REFERENCES

- Hosteller JA. History and relevance of the Hutterite population for genetic studies. *Am J Med Genet* 1985;**22**:453–362.
- Barth PG, Valianpour F, Bowen VM, Lam J, Duran M, Vas FM, Wanders RJ. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update. *Am J Med Genet A* 2004;**126**:349–54.
- Ly TB, Peters V, Gibson KM, Liesert M, Buckel W, Wilcken B, Carpenter K, Ensenaer R, Hoffmann GF, Mack M, Zschocke J. Mutations in the AUH gene cause 3-methylglutaconic aciduria type I. *Hum Mutat* 2003;**21**:401–7.
- Anikster Y, Kleit R, Shaag A, Gahl WA, Elpeleg O. Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews. *Am J Hum Genet* 2001;**69**:1218–24.
- Gunay-Aygun M. 3-Methylglutaconic aciduria: a common biochemical marker in various syndromes with diverse clinical features. *Mol Genet Metab* 2005;**84**:1–3.
- Lander ES, Botstein D. Homozygosity mapping: a way to map human recessive traits with the DNA of inbred children. *Science* 1987;**236**:1567–70.
- Kelley RI. Quantification of 3-methylglutaconic acid in urine, plasma, and amniotic fluid by isotope-dilution gas chromatography/mass spectrometry. *Clin Chim Acta* 1993;**220**:157–64.
- Taylor SW, Fahy E, Zhang B, Glenn GM, Warnock DE, Wiley S, Murphy AN, Gaucher SP, Capaldi RA, Gibson BW, Ghosh SS. Characterization of the human heart mitochondrial proteome. *Nat Biotechnol* 2003;**21**:281–6.
- Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. *Cell Mol Life Sci* 2005;**62**:670–84.
- Ohtsuka K, Hata M. Mammalian HSP40/DNAJ homologs: cloning of novel cDNAs and a proposal for their classification and nomenclature. *Cell Stress Chaperones* 2000;**5**:98–112.
- Westermann B, Neupert W. Mj2p, a novel DnaJ homolog in the mitochondrial inner membrane of the yeast *Saccharomyces cerevisiae*. *J Mol Biol* 1997;**272**:477–83.
- Mokranjac D, Sighting M, Neupert W, Hell K. Tim14, a novel key component of the import motor of the TIM23 protein translocase of mitochondria. *Embo J* 2003;**22**:4945–56.
- Truscott KN, Voos W, Frazier AE, Lind M, Li Y, Geissler A, Dudek J, Muller H, Sickmann A, Meyer HE, Meisinger C, Guiard B, Rehling P, Pfanner N. A J-protein is an essential subunit of the presequence translocase-associated protein import motor of mitochondria. *J Cell Biol* 2003;**163**:707–13.
- D'Silva PD, Schilke B, Walter W, Andrew A, Craig EA. J protein cochaperone of the mitochondrial inner membrane required for protein import into the mitochondrial matrix. *Proc Natl Acad Sci USA* 2003;**100**:13839–44.
- Frazier AE, Dudek J, Guiard B, Voos W, Li Y, Lind M, Meisinger C, Geissler A, Sickmann A, Meyer HE, Bilanchone V, Cumsy MG, Truscott KN, Pfanner N, Rehling P. Pam 16 has an essential role in the mitochondrial protein import motor. *Nat Struct Mol Biol* 2004;**11**:226–33.
- Kozany C, Mokranjac D, Sighting M, Neupert W, Hell K. The J domain-related cochaperone Tim16 is a constituent of the mitochondrial TIM23 preprotein translocase. *Nat Struct Mol Biol* 2004;**11**:234–41.
- Burri L, Vascotto K, Fredersdorf S, Tiedt R, Hall MN, Lithgow T. Zim17, a novel zinc finger protein essential for protein import into mitochondria. *J Biol Chem* 2004;**279**:50243–9.
- Yamamoto H, Momose T, Yatsukawa Y, Ohshima C, Ishikawa D, Sato T, Tamura Y, Ohwa Y, Endo T. Identification of a novel member of yeast mitochondrial Hsp70-associated motor and chaperone proteins that facilitates

- protein translocation across the inner membrane. *FEBS Lett* 2005;**579**:507–11.
- 19 Rehling P, Pfanner N, Meisinger C. Insertion of hydrophobic membrane proteins into the inner mitochondrial membrane – a guided tour. *J Mol Biol* 2003;**326**:639–57.
 - 20 Shridhar V, Bible KC, Staub J, Avula R, Lee YK, Kalli K, Huang H, Hartmann LC, Kaufmann SH, Smith DL. Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. *Cancer Res* 2001;**61**:4258–65.
 - 21 Strathdee G, Davies BR, Vass JK, Siddiqui N, Brown R. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene. *Carcinogenesis* 2004;**25**:693–701.
 - 22 Strathdee G, Vass JK, Oien KA, Siddiqui N, Curto-Garcia J, Brown R. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. *Gynecol Oncol* 2005;**97**:898–903.
 - 23 Tranebjaerg L, Schwartz C, Eriksen H, Andreasson S, Ponjavic V, Dahl A, Stevenson RE, May M, Arena F, Barker D. A new X linked recessive deafness syndrome with blindness, dystonia, fractures, and mental deficiency is linked to Xq22. *J Med Genet* 1995;**32**:257–63.
 - 24 Jin H, May M, Tranebjaerg L, Kendall E, Fontan G, Jackson J, Subramony SH, Arena F, Lubbs H, Smith S, Stevenson R, Schwartz C, Vetrie D. A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency and blindness. *Nat Genet* 1996;**14**:177–80.
 - 25 Rothbauer U, Hofmann S, Muhlenbein N, Paschen SA, Gerbitz KD, Neupert W, Brunner M, Bauer MF. Role of the deafness dystonia peptide 1 (DDP1) in import of human Tim23 into the inner membrane of mitochondria. *J Biol Chem* 2001;**276**:37327–34.

BOOK REVIEW

Oxford desk reference: clinical genetics

Authored by H V Firth, J A Hurst. Oxford: Oxford University Press, 2005, pp 708. ISBN 0-19-262896-8

If there was a Booker Prize for new texts on clinical genetics, then the winner this year would be a foregone conclusion. No one else could possibly come up with an entry as good as this. Somehow, squeezed in between busy careers and presumably equally demanding family lives, Helen Firth and Jane Hurst have found the time to compile the definitive hands-on guide to clinical genetics.

The authors have chosen to divide their working manual into seven sections, beginning with an introduction covering the basic principles of Mendelian inheritance and tools of genetic counselling, and concluding with an extremely comprehensive review of pregnancy/fertility related genetic problems. This

will prove to be particularly valuable as clinical geneticists increasingly find themselves invited to interpret and counsel for abnormal prenatal ultrasound findings. The bulk of the text, consisting of over 500 closely typed pages, is subdivided into four sections entitled Clinical Approach, Common Consultations, Cancer, and Chromosomes. These provide coverage of several hundred clinical scenarios and diagnostic challenges, comprising almost every situation that a clinical geneticist is likely to encounter in day to day practice. Each entry has been meticulously prepared, so that if we open the book randomly at, say, microcephaly or autism or breast cancer, each condition is defined, a practical clinical approach (history, examination, and investigations) is outlined, there is an apt and succinct discussion of possible differential diagnoses, and the topic is rounded off with guidelines for counselling on recurrence risks, carrier detection, and prenatal diagnosis. The small print at the end of each entry provides useful references with details of the relevant support group and an acknowledged authority who acted as an “expert adviser”. It says much for the persuasive powers of the authors that they succeeded in ensuring that every entry—remember there are several hundred—was

reviewed by a colleague with recognised expertise. The book is completed by an extremely useful appendix consisting of 55 pages of charts and tables.

This “desk reference” will rapidly become as indispensable as OMIM and the London Dysmorphology Database. The breadth and depth of information provided is remarkable.

All the entries have been chosen carefully and the information provided is always comprehensive, relevant, and up to date. As a practical guide to the specialty of clinical genetics this book has no match, and overall it represents an awesome achievement. How did the authors manage to acquire and collate all this knowledge? Where did they find all this information? Clearly they have little consideration for their peers who slave away over the word processor writing text books that they have now rendered obsolete! And how are we all going to find a pocket big enough to conceal this treasure trove when we visit the ward or a peripheral clinic? If your department can only afford one book this year, make it this one. Better still, buy your own copy and keep it hidden because it is going to be much in demand.

Ian Young